Seroprevalence after vaccination of cattle and sheep against Bluetongue Virus (BTV) serotype 8 in Sweden.
Sweden experienced its first outbreak of bluetongue virus (BTV) infection beginning in September 2008. Mandatory vaccination with an inactivated vaccine (BTVPUR Alsap8; Merial, Lyon, France) began 2 days after bluetongue was confirmed in the country. The aim of this study was to investigate whether the goal of 80% seroconversion by the susceptible population within the vaccination area was met during the initial phase of the Swedish vaccination campaign and whether there were discrepancies between subpopulations. Milk or blood samples were collected from 274 cattle randomly selected from the vaccinated population. Blood samples were also collected from ten ewes on each of 28 randomly selected vaccinated herds. The vaccination campaign in Sweden may be regarded as successful, as measured by apparent seroprevalence in the vaccinated population. The overall apparent seroprevalence was 77%, and in cattle, which constituted the majority of the susceptible population, the apparent seroprevalence was 82%. Factors that influenced the titres after vaccination were as follows: (i) the time span between vaccination and sampling and (ii) the age of the animals.
Department of Disease Control and Epidemiology, National Veterinary Institute, SE-751 89 Uppsala, Sweden. cecilia.hulten@sva.se
C
C
Hultén
J
J
Frössling
E
E
Chenais
S
S
Sternberg Lewerin
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis* / Q000097:blood; D001819:Bluetongue / Q000453:epidemiology / Q000517:prevention & control*; D001820:Bluetongue virus / Q000276:immunology*; D002417:Cattle / Q000276:immunology*; D002418:Cattle Diseases / Q000453:epidemiology / Q000517:prevention & control; D005260:Female; D008297:Male; D032541:Mass Vaccination / Q000662:veterinary*; D008892:Milk / Q000276:immunology; D016036:Seroepidemiologic Studies; D012756:Sheep / Q000276:immunology*; D013548:Sweden / Q000453:epidemiology; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
D000914:Antibodies, Viral; D015164:Vaccines, Inactivated; D014765:Viral Vaccines